查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1878291

镰状细胞疾病治疗市场－2025-2030年预测

Sickle Cell Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2030 年，镰状细胞疾病治疗市场规模将从 2025 年的 27.94 亿美元成长至 80.53 亿美元，复合年增长率为 23.58%。

镰状细胞疾病治疗市场：产业专业人士的策略概览

镰状细胞疾病 (SCD) 治疗市场的特点是未满足的医疗需求、不断发展的治疗格局以及全球公共卫生协调努力之间的动态相互作用。 SCD 是一种永久性、致残性遗传性血液疾病，主要影响撒哈拉以南非洲、西班牙裔、南亚裔、南欧裔和中东裔人群。此疾病的特征是镰状和慢性併发症，包括镰状细胞疼痛危机、急性胸痛症候群、溶血性贫血和进行性性器官损伤，并且与预期平均寿命缩短和儿童期发病有关。由于历史上缺乏能够同时解决 SCD 根本病因和多方面併发症的治疗方法，这为药物创新和市场成长创造了巨大的机会。

镰状细胞疾病治疗市场的主要驱动力之一是世界各国政府和非营利组织积极采取措施。镰状细胞疾病对社会带来沉重负担，尤其是在儿童群体中，促使各国制定有针对性的福利政策。例如，印度卫生和家庭福利部宣布了一项雄心勃勃的计划，旨在到2047年根除镰状细胞贫血，并为此拨付了专案预算。该计划已促成大规模筛检活动，并透过国家卫生使命提供包括羟基脲和输血在内的免费治疗。同时，世界银行等国际组织正在透过促进公立和私人医疗机构之间的合作，扩大非洲的镰状细胞疾病治疗性介入。此外，美国国立卫生研究院等机构正在投入大量资金进行研究，旨在解决镰状细胞疾病患者在医疗保健方面面临的不平等问题。这些在资金筹措、提高公众意识和项目拓展方面的多国合作努力，为市场扩张奠定了坚实的基础。

儘管有这些驱动因素，市场仍面临一个重大限制因素：长期以来缺乏针对镰状细胞疾病根本遗传病因的治疗方法。目前的标准治疗方案——例如镰状等药物疗法、输血和骨髓移植——主要以安宁疗护为主。虽然这些疗法着重于症状控制、降低併发症和死亡率，但并不能治癒根本疾病。此外，干细胞移植等根治性治疗方法本身存在显着风险，限制了其广泛应用。这种治疗方法缺口历来限制市场的快速成长。然而，正是这项挑战，正在推动该领域最具变革性的趋势：转型为更先进、可能治癒的治疗方法。

塑造该市场未来发展的最重要趋势是对创新疗法，特别是细胞和基因疗法的重点关注和大力投资。各大製药公司正积极致力于基因修饰疗法的研发，以解决镰状细胞疾病（SCD）的根本遗传缺陷，这标誌着模式转移寻求持久治癒。监管环境也在同步发展，美国食品药物管理局（FDA）等机构正在对新型治疗方法进行监管。产业策略整合也在进行中，旨在加强产品线的大规模收购，尤其是在血液学和SCD领域，便是明证。这些合作和高价值投资正在加速根治性治疗方法的研发进程，并预示着SCD治疗领域即将迎来新纪元。

从地理来看，市场前景在两大关键区域表现强劲。北美市场预计将迎来成长，这主要得益于镰状细胞疾病（SCD）的高发生率，尤其是在非裔美国人群体中，以及大型製药公司和研究机构的存在。主要产业参与者持续的研发投入，加上相对较高的可支配收入水准和先进的医疗基础设施，预计将推动对先进SCD治疗方法日益增长的需求。中东和非洲地区也因其极高的SCD发病率而被视为关键成长区域。许多非洲国家的SCD带菌率和盛行率位居世界前列。此外，国际卫生组织和区域政府不断加强宣传和预防宣传活动，预计将在预测期内显着刺激SCD治疗方案的需求和消费。

总之，镰状细胞疾病治疗市场正处于转折点。该市场传统上以安宁疗护和有限的治疗选择为主导，如今正因全球公共卫生倡议和突破性科学创新而焕发新生。各国政府和非营利组织的共同努力正在扩大患者群体并改善诊断基础设施，而製药业对基因和细胞疗法的探索有望重新定义治疗标准。儘管非洲地区巨大的未满足需求既带来了挑战也带来了机会，但公共卫生策略与尖端生物医学科学的融合正推动整个市场走上显着扩张和转型的道路。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：对Start-Ups、研究机构、顾问公司、中小企业和大型企业都很有用且经济实惠。

公司如何使用我们的报告范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2022年至2024年的历史数据和2025年至2030年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家/地区）分類的收入成长和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章镰状细胞疾病治疗市场（依疗法分类）

  • 介绍
  • 输血疗法
  • 药物治疗
  • 骨髓移植

第六章 依最终使用者镰状细胞疾病治疗市场

  • 介绍
  • 医院
  • 诊断中心
  • 其他的

第七章镰状细胞疾病治疗市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第九章：公司简介

  • Novartis AG
  • Bluebird bio, Inc.
  • Agios Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Emmaus Medical, Inc.
  • Bristol-Myers Squibb Company
  • Addmedica
  • Modus Therapeutics AB
  • Crispr Therapeutics
  • Sancilio Pharmaceuticals Company, Inc.

第十章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061614880

The sickle cell disease treatment market is projected to expand at a 23.58% CAGR, achieving USD 8.053 billion by 2030 from USD 2.794 billion in 2025.

Sickle Cell Disease Treatment Market: A Strategic Overview for Industry Experts

The Sickle Cell Disease (SCD) treatment market is characterized by a dynamic interplay of significant unmet medical needs, evolving therapeutic landscapes, and concerted global public health efforts. SCD is a permanent and disabling genetic blood disorder, predominantly affecting populations with ancestry from sub-Saharan Africa, as well as Hispanic, South Asian, Southern European, and Middle Eastern communities. The disease is marked by acute and chronic complications-including sickle pain crises, acute chest syndrome, hemolytic anemia, and progressive organ damage-that begin in childhood and are associated with reduced life expectancy. The historical shortage of therapies addressing both the underlying etiology and the multifaceted complications of SCD has created a substantial opportunity for pharmaceutical innovation and market growth.

A primary driver propelling the SCD treatment market forward is the surge in favorable initiatives from governments and non-profit organizations (NPOs) worldwide. The profound burden of SCD, particularly on pediatric populations, is catalyzing the formulation of targeted welfare policies. For instance, the Ministry of Health and Family Welfare in India has announced ambitious plans for the elimination of sickle cell anemia by 2047, underpinned by specific budgetary allocations. This has already translated into large-scale screening initiatives and the provision of free treatment, including hydroxyurea and blood transfusions, through the National Health Mission. Concurrently, international bodies like the World Bank are scaling up SCD treatment interventions across Africa by fostering integration between public and private healthcare sectors. Furthermore, significant research funding from institutions such as the US National Institutes of Health is being directed toward alleviating healthcare disparities for SCD patients. This collective, multi-national commitment to funding, awareness, and program expansion is establishing a robust foundation for market expansion.

Despite these drivers, the market faces a significant constraint: the historical unavailability of therapies that target the root genetic cause of Sickle Cell Disease. Current standard-of-care treatments, including pharmacotherapy with drugs like hydroxyurea, blood transfusions, and bone marrow transplantation, are primarily palliative. They focus on symptom management, reducing the frequency of complications, and lowering mortality rates but do not offer a cure for the underlying condition. The inherent and prominent risks associated with curative-intent procedures like stem cell transplantation further limit their widespread application. This therapeutic gap has historically restrained more rapid market growth. However, this very challenge is now fueling the most transformative trend in the sector: the pivot towards advanced, potentially curative treatment modalities.

The most pivotal development shaping the future of this market is the intense focus and investment in innovative therapeutic approaches, particularly cell and gene therapies. Leading pharmaceutical companies are actively engaged in the research and development of gene-altering therapies designed to address the fundamental genetic defect of SCD. This represents a paradigm shift from managing symptoms to pursuing durable cures. The regulatory landscape is evolving in tandem, with agencies like the U.S. Food and Drug Administration engaging with novel therapies. The industry is also witnessing strategic consolidation, as evidenced by major acquisitions aimed at bolstering pipelines in hematology and SCD specifically. These collaborations and high-value investments are accelerating the advancement of curative treatment options, signaling a new era for the SCD treatment landscape.

From a geographical perspective, the market outlook is robust across two key regions. In North America, the market is poised for growth driven by the high prevalence of SCD, particularly within the African American community, and the presence of leading pharmaceutical companies and research institutions. Continuous research and development efforts by key industry players, combined with relatively high disposable income levels and advanced healthcare infrastructure, are expected to fuel the consumption of advanced SCD treatments. The Middle East and Africa region represents another critical growth area, largely due to the exceptionally high prevalence rates of SCD. In many African nations, carrier rates and disease prevalence are among the highest globally. This, coupled with increasing initiatives from international health organizations and regional governments to launch awareness and prevention campaigns, is expected to significantly stimulate the demand and consumption of SCD treatments throughout the forecast period.

In conclusion, the Sickle Cell Disease treatment market is at an inflection point. It is transitioning from a space long defined by palliative care and limited options to one energized by global public health initiatives and groundbreaking scientific innovation. The concerted efforts of governments and NPOs are expanding the addressable patient base and improving diagnostic infrastructure, while the pharmaceutical industry's pursuit of gene and cell therapies promises to redefine the standard of care. While the high unmet need in regions like Africa presents both a challenge and an opportunity, the overall market trajectory is set toward significant expansion and transformation, driven by the convergence of public health strategy and cutting-edge biomedical science.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Sickle Cell Disease Treatment Market Segmentation:

  • SICKLE CELL DISEASE TREATMENT MARKET BY TREATMENT
  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant
  • SICKLE CELL DISEASE TREATMENT MARKET BY END-USER
  • Hospitals
  • Diagnostic Centers
  • Others
  • SICKLE CELL DISEASE TREATMENT MARKET BY GEOGRAPHY
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SICKLE CELL DISEASE TREATMENT MARKET BY TREATMENT

  • 5.1. Introduction
  • 5.2. Blood Transfusion
  • 5.3. Pharmacotherapy
  • 5.4. Bone Marrow Transplant

6. SICKLE CELL DISEASE TREATMENT MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals
  • 6.3. Diagnostic Centers
  • 6.4. Others

7. SICKLE CELL DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Novartis AG
  • 9.2. Bluebird bio, Inc.
  • 9.3. Agios Pharmaceuticals, Inc.
  • 9.4. Pfizer Inc.
  • 9.5. Emmaus Medical, Inc.
  • 9.6. Bristol-Myers Squibb Company
  • 9.7. Addmedica
  • 9.8. Modus Therapeutics AB
  • 9.9. Crispr Therapeutics
  • 9.10. Sancilio Pharmaceuticals Company, Inc.

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations